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A B S T R A C T
Background: To maximize protection against stroke with minimal bleeding, warfarin therapy in
nonvalvular atrial ﬁbrillation (NVAF) requires tight control within a narrow therapeutic range, which
might depend on racial variations.
Methods: The J-RHYTHM Registry followed 6404 NVAF patients treated with warfarin for 2 years. Using
international normalized ratios (INRs) at or closest to the embolic and intracranial hemorrhagic (ICH)
events, we determined odds ratios for ischemic stroke/systemic embolism (SE) and ICH according to any
given INR with a reference INR range including 2.0.
Results: Ischemic stroke and SE occurred in 97 of the patients and ICH occurred in 49. The estimated INR-
risk relationships showed characteristics of Japanese NVAF patients. Compared to INR-risk relationships
reported for Westerners, those observed in Japanese patients were virtually identical for ischemic
stroke/SE and shifted leftward by approximately 0.5 INR for ICH.
Conclusion: This is the largest Japanese study providing fundamental data necessary to establish optimal
anticoagulation intensities. Japanese NVAF patients may require narrower therapeutic ranges than
Westerners.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Warfarin anticoagulation can prevent ischemic stroke and
peripheral embolism in atrial ﬁbrillation (AF) patients. AF
management guidelines in Western countries recommend target
prothrombin time-international normalized ratio (PT-INR) levels
of 2–3, irrespective of age and CHADS2 score [1]. However, racial
differences have an impact on the risk of intracranial hemorrhage
(ICH) under warfarin treatment, which is higher in Asians than in
Caucasians [2]. Therefore, optimal anticoagulation therapeutic
ranges should consider racial differences [3]. The J-RHYTHM
Registry tracked 2-year clinical outcomes and anticoagulation
levels for over 7500 patients with nonvalvular AF (NVAF) [4–6].DOI of commentary article: http://dx.doi.org/10.1016/j.jjcc.2014.09.003
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsRecently, we analyzed relationships between PT-INR at enrollment
and clinical outcomes [6]. However, optimal INR levels can be
better evaluated using PT-INRs at or close to clinical events. We
determined the odds ratios (ORs) for ischemic stroke/systemic
embolism (SE) and ICH using INRs at or closest to embolic and
hemorrhagic events in Japanese NVAF patients.
Materials and methods
Details of the study design and subjects’ baseline characteristics
are reported elsewhere [4,5]. Consecutive AF patients were recruited
from outpatient clinics of 158 participating institutions. The J-
RHYTHM Registry enrolled 7937 AF patients (mean age, 69.7 years),
including 421 with mitral stenosis or mechanical valve replacement.
Of the 7516 NVAF patients, 6404 warfarin-treated patients were
included in the present study. In the present study, ischemic stroke/
SE and ICH including hemorrhagic stroke were analyzed. Using INRs
at or closest before these events, ORs for ischemic stroke/SE and ICH
were determined as previously reported [7,8]. reserved.
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Categorical and consecutive data are presented as number (%)
and mean  standard deviation, respectively. The chi-square and
unpaired t-tests were used for group comparisons. INRs at the event
or closest prior date were used for cases and INRs at the same follow-
up period were used for event-free controls. ORs with 95% conﬁdence
intervals (CIs) were calculated by logistic regression with INR and
CHADS2 score as variables. Similar to previous reports [6,7], INRs
were categorized by 0.2 and 0.5 INR steps for ischemic stroke/SE and
ICH, respectively. The OR at each INR category was normalized to 1.0
at an INR range including 2.0 (1.8 < INR  2.0 for stroke/SE and
1.5 < INR  2.0 for ICH). Statistical signiﬁcance was set at p < 0.05.
Results
During 2 years of warfarin treatment, 97 ischemic stroke/SE and
49 ICH events occurred in 6404 NVAF patients. Table 1 shows the
characteristics of patients with and without these events.
Compared with controls, ischemic stroke/SE patients were older
and had higher CHADS2 scores with a greater prevalence of stroke/
transient ischemic attack (TIA) history. ICH patients were older andFig. 1. Odds ratio for ischemic stroke/systemic embolism (left) and intracranial hemorrha
ischemic stroke/systemic embolism and intracranial hemorrhage as compared with INR





n 6404 97 6307 
Male 4536 (70.8) 69 (71.1) 4467 (70.8)
Age 70.1  9.6 74.9  8.3 70.0  9.6
CAD 687 (10.7) 14 (14.4) 673 (10.7)
CHF 1900 (29.7) 34 (35.1) 1866 (29.6)
Hypertension 3943 (61.6) 60 (61.9) 3883 (61.6)
DM 1223 (19.1) 24 (24.7) 1199 (19.0)
History of stroke/TIA 955 (14.9) 22 (22.7) 933 (14.8)
CHADS2 score 1.8  1.2 2.2  1.1 1.7  1.2
PT-INR (mean) 1.97  0.56 1.74  0.58 1.98  0.
<1.4 647 (10.1) 31 (32.0) 616 (9.8) 
1.42 22.5 4945 (77.2) 57 (58.8) 4888 (77.5)
2.5< 812 (12.7) 9 (9.3) 803 (12.7)
CAD, coronary artery disease; CHF, congestive heart failure; DM, diabetes mellitus; TI
ratio.had higher CHADS2 scores with greater prevalence of congestive
heart failure and stroke/TIA history.
Ischemic stroke/TIA and ICH occurred at a median follow-up of
318  181 days and 335  215 days, respectively. INR at the event
was obtained in 59 ischemic stroke/SE and 41 ICH patients. Among
the remaining patients, the mean time-lag between events and the
closest INR was 38  35 days (n = 38) and 58  59 days (n = 8),
respectively. Using these PT-INRs, ORs for ischemic stroke/SE and ICH
were estimated as a function of INR. Fig. 1 shows ORs for ischemic
stroke/SE and ICH as compared to an INR including 2.0 after
adjustment for CHADS2 score, and the detailed risk ratios are shown
in Table 2. We observed no signiﬁcant interaction between age and
INR-risk relationships (data not shown).
The risk of ischemic stroke/SE rose gradually as INR values fell
below 2.0 and steeply as they fell below 1.6. Patients with INRs of
1.2–1.4 had a high risk of 3.01 vs. those with INRs of 1.8–2.0 (95% CI
1.45–6.23). The risk of ICH rose as INR values exceeded 2.5. Patients
with INRs of 2.5–3.0 had a remarkably high risk of 4.22 (95% CI
1.81–9.84) vs. those with INRs of 1.5–2.0. Even when we analyzed
data excluding the case patients with only INRs at the closest day
not at the events, we could not ﬁnd any signiﬁcant alterations in
these INR-risk relationships.ge (right) vs. international normalized ratio (INR) value. This represents the odds of
s of 1.8–2.0 and 1.5–2.0, respectively. Each point in the X-axis indicates the median
c embolism Intracranial hemorrhage
p value With Without p value
49 6355
 0.9472 40 (81.6) 4496 (70.7) 0.0949
 <0.0001 73.7  9.9 70.0  9.6 0.0082
 0.2347 5 (10.2) 682 (10.7) 0.9054
 0.2422 21 (42.9) 1879 (29.6) 0.0425
 0.9537 37 (75.5) 3906 (61.5) 0.0440
 0.1541 12 (24.5) 1211 (19.1) 0.3350
 0.0305 19 (38.8) 936 (14.7) <0.0001
 <0.0001 2.8  1.3 1.7  1.2 <0.0001
56 <0.0001 2.41  1.33 1.98  0.58 <0.0001
8 (16.3) 651 (10.2)
 <0.0001 24 (49.0) 4906 (77.2) <0.0001
 17 (34.7) 798 (12.6)
A, transient ischemic attack; PT-INR, prothrombin time-international normalized
Table 2
Relative risk according to PT-INR.
PT-INR N Odds ratio 95% CI p value
Ischemic stroke/systemic embolism
1.02 21.2 226 6.732 3.23–14.05 <0.0001
1.2< 21.4 457 3.014 1.46–6.23 0.0029
1.4< 21.6 805 1.721 0.83–3.55 0.1417
1.6< 21.8 1157 1.038 0.49–2.19 0.9221
1.8< 22.0 1204 1.000 –
2.0< 22.2 883 0.383 0.13–1.17 0.0915
2.2< 22.4 622 0.546 0.18–1.67 0.2873
2.4< 22.6 424 0.833 0.27–2.55 0.7484
2.6< 22.8 256 1.002 0.29–3.52 0.9972
2.8< 23.0 153 1.778 0.50–6.27 0.3711
3.0< 24.0 173 0.993 0.22–4.41 0.9922
4.0< 44 1.788 0.23–13.95 0.5793
Intracranial hemorrhage
1.02 21.5 1003 1.999 0.84–4.76 0.1182
1.5< 22.0 2808 1.000 –
2.0< 22.5 1757 1.497 0.66–3.40 0.3358
2.5< 23.0 579 4.220 1.81–9.84 0.0009
3.0< 24.0 184 5.112 1.63–16.07 0.0052
4.0< 52 12.262 3.33–45.20 0.0002
Bold values represent the reference at an INR range including 2.0.
PT-INR, prothrombin time-international normalized ratio; CI, conﬁdence interval.
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This study explored the relation of anticoagulation levels to
ischemic stroke/SE and ICH for primary and secondary prevention
in Japanese NVAF patients. The large size, prospective design, and
analysis of event-nearest INRs emphasize study signiﬁcance [7,8].
While the INR-risk relationships for ischemic stroke/SE were
virtually identical to those in Westerners, ICH relationships shifted
leftward by approximately 0.5 of INR.
Two retrospective studies suggested that appropriate INRs for
minimizing major hemorrhages in elderly Japanese NVAF patients
with a history of stroke/TIA [9] or high CHADS2 score 2 [10]
would be lower than in Westerners. The present study supports
this notion for many Japanese NVAF patients, showing an
occurrence of ICH approximately four times greater at an INR
>2.5 than at an INR of 1.5–2.0.
However, an important issue emerged regarding the lowest
effective anticoagulation intensity for Japanese NVAF patients. We
observed a tendency of gradual increase in risk of ischemic stroke/
SE below an INR of 2.0, similar to Westerners. Moreover, no
signiﬁcant interaction was observed between patient age and INR-
stroke/SE risk relationships. By contrast, the prior retrospective
studies observed no stroke/SE increase in the 1.5–2.0 INR range
[9,10]. Differences in patient characteristics, study design (pro-
spective/retrospective and multicenter/single center), and cohort
size may explain this apparent difference.
Despite being large, the present study is not statistically
powerful enough to determine risk differences around an INR of 2.0
and by patient age. Therefore, the lowest effective anticoagulation
intensity for Japanese NVAF patients requires further study with
longer follow-ups [11].
Limitations include the observational design, physician-deter-
mined anticoagulation levels, and limited 2-year follow-up. In
addition, the number of patients with INR >2.5 was relatively
small as compared with other categories. Although limited, this is
the largest study providing fundamental data on INR-event
relationships in Japanese NVAF patients.
Conclusions
In Japanese NVAF patients as compared with Westerners, the
estimated INR-risk relationships were virtually identical forischemic stroke/SE but shifted leftward by approximately 0.5
INR for ICH, resulting in narrower therapeutic ranges with vitamin
K antagonists.
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